Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06059963

A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation

To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.

Recruiting

Interested in participating?

Request Info

Key information

Age range

45 year–84 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Gastroenterology Consultants of SW Virginia

Raonoke, Virginia, 24014, United States

Location status: Recruiting

Location contact

Vishal Bhagat

CONTACT

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects aged 45-84 years at time of consent
  • Intended to undergo a standard-of-care screening colonoscopy
  • Considered by a physician or healthcare provider as being of 'average risk' for CRC
  • Willing to consent to blood draw prior to bowel preparatory procedures or undergoing colonoscopy ideally within 90 days of the date of the investigational blood draw.
  • Willing to consent to follow-up for one year as per protocol
  • Able and willing to sign informed consent

Exclusion criteria

  • Undergoing colonoscopy for investigation of CRC risk symptoms
  • Has undergone colonoscopy within preceding 9 years
  • Positive FIT/FOBT result within the previous 12 months (+/- 3 months)
  • Has completed Cologuard or Epi proColon testing within the previous 3 years.
  • Has undergone a CT colonography in the prior 4 years.
  • History of colorectal cancer.
  • History of any malignancy within prior 5 years.
  • Known diagnosis of inflammatory bowel disease (IBD), including chronic ulcerative colitis (CUC) and Crohn's disease (CD).
  • Positive family history of colorectal cancer, defined as having a first- degree relative (parent, sibling, or child) with CRC diagnosed at age <60 years or with more than one first-degree relative diagnosed with CRC at any age.
  • Known hereditary/germline risk of colorectal cancer (for example, Lynch syndrome or Hereditary Non-Polyposis CRC [HNPCC], or Familial Adenomatous Polyposis [FAP]).
  • Any major physical trauma (e.g., disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent.
  • Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study.
  • Known pregnancy at informed consent, blood sample collection, and during study participation.
  • Participation in a clinical research study in which an experimental medication has been administered or may be administered within the 30 days leading up to providing informed consent or may be administered through the time of colonoscopy.

Treatment and study plan

Signal-C™

Device

Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).

Primary outcomes

  1. Primary Objective

    Time frame: 1 year

    The primary objective of this study is to determine the sensitivity for CRC and specificity for advanced neoplasia (AN). Advance Neoplasia (AN) is defined as a final diagnosis of CRC or Advanced Precancerous Lesion (APL).

Secondary outcomes

  1. Secondary Objective

    Time frame: 1 year

    To determine sensitivity for advanced precancerous lesions (APL). To determine NPV and PPV for colorectal cancer.

Study contacts

Contact information is provided by the study sponsor or research team.

Kara Mattox

CONTACT

[email protected]

(+1)3392085320

Sponsors and collaborators

Lead sponsor

Universal Diagnostics

Industry

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Sep 29, 2023
Registry last updated
Nov 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.